General description
Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits angiogenesis. It is used in the treatment of vascular eye diseases and in treatment protocols for some cancers.
INN
Bevacizumab
ATC codes
Medicine type
Biological agent
EML status history
First added in 2013
(TRS
985)
for
Age related macular degeneration
Wikipedia
DrugBank
Recommendations
Section
Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations
- Parenteral > Locoregional injections > Intravitreal: 25 mg per mL
Indications